FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Incyte Corporation
Incyte Corporation A Delaware Corporation
Incyte Corporationn A Delaware Corporation

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Incyte Corporation patents


      
Recent patent applications related to Incyte Corporation. Incyte Corporation is listed as an Agent/Assignee. Note: Incyte Corporation may have other listings under different names/spellings. We're not affiliated with Incyte Corporation, we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Incyte Corporation-related inventors



Search recent Press Releases: Incyte Corporation-related press releases
Count Application # Date Incyte Corporation patents (updated weekly) - BOOKMARK this page
12010002252201/28/10Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
22014031596210/23/14 new patent  1,2,5-oxadiazoles as inhibitors of indoleamine 2,3- dioxygenase
32014027503009/18/14Tricyclic heterocycles as bet protein inhibitors
42014027503109/18/14Piperidin-4-yl azetidine derivatives as jak1 inhibitors
52014027512709/18/14Substituted heteroaryl fused derivatives as pi3k inhibitors
62014025694109/11/14Processes and intermediates for making a jak inhibitor
72014024913209/04/14Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
82014024208608/28/14Polynucleotides encoding signal peptide-containing molecules
92014024330808/28/14Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
102014024336008/28/14Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
112014022727508/14/14Methods of treating and diagnosing pancreatitis
122014022727808/14/14Antibodies to human signal peptide-containing proteins
132014022834608/14/14Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
142014022137908/07/14N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
152014020021607/17/14Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
162014020022707/17/14Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
172014018753007/03/14Aza spiro alkane derivatives as inhibitors of metalloproteases
182014017140506/19/14Fused pyrazoles as fgfr inhibitors
192014017140906/19/14Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
202014015528806/05/14Methods for diagnosing cancer
212014015537706/05/143-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
222014015540406/05/14Piperazinylpiperidine derivatives as chemokine receptor antagonists
232014013535005/15/14Sustained-release dosage forms of ruxolitinib
242014013535005/15/14Sustained-release dosage forms of ruxolitinib
252014012119805/01/14Tricyclic fused thiophene derivatives as jak inhibitors
262014012122205/01/14Pyrimidinones as pi3k inhibitors
272014012119805/01/14Tricyclic fused thiophene derivatives as jak inhibitors
282014012122205/01/14Pyrimidinones as pi3k inhibitors
292014006644803/06/14Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
302014006644803/06/14Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
312014005690602/27/14Secreted proteins
322014005791202/27/14Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
332014004581402/13/14Pyrazine derivatives as fgfr inhibitors
342014003134401/30/14Azepine inhibitors of janus kinases
352014002366301/23/141,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
362014001837401/16/14Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
372014000516601/02/14Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
382014000521001/02/14Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
392013034515712/26/13Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
402013034522412/26/13Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
412013032451512/05/13Imidazotriazines and imidazopyrimidines as kinase inhibitors
422013025319009/26/13Processes for preparing jak inhibitors and related intermediate compounds
432013025319109/26/13Processes for preparing jak inhibitors and related intermediate compounds
442013025319309/26/13Processes for preparing jak inhibitors and related intermediate compounds
452013024378109/19/13Signal peptide-containing proteins
462013024492709/19/13Polynucleotides encoding signal peptide-containing molecules
472013024499909/19/13Substituted heterocyclic compounds
482013022476908/29/13Methods of using chemokine panec-1 antibodies
492013022555608/29/13Azetidine and cyclobutane derivatives as jak inhibitors
502013022476908/29/13Methods of using chemokine panec-1 antibodies
512013022555608/29/13Azetidine and cyclobutane derivatives as jak inhibitors
522013019025007/25/13Polynucleotides encoding human signal peptide-containing proteins
532013019025007/25/13Polynucleotides encoding human signal peptide-containing proteins
542013017759007/11/13N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
552013017759007/11/13N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
562013013768105/30/13Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
572013013768105/30/13Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
582013012324605/16/13Modulators of indoleamine 2,3-dioxygenase and methods of using the same
592013012324605/16/13Modulators of indoleamine 2,3-dioxygenase and methods of using the same
602013011623005/09/133-aminopyrrolidine derivatives as modulators of chemokine receptors
612013011623005/09/133-aminopyrrolidine derivatives as modulators of chemokine receptors
622013009614404/18/13Isoindolinone and pyrrolopyridinone derivatives as akt inhibitors
632013005894203/07/13Human beta-adrenergic receptor kinase polypeptide and methods
642013005983503/07/13Heterocyclylamines as pi3k inhibitors
652013006002603/07/13Processes and intermediates for making a jak inhibitor
662013004596302/21/13Cyclohexyl azetidine derivatives as jak inhibitors
672013001803401/17/13Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
682013001806801/17/13Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1
692012032978212/27/12Azepine inhibitors of janus kinases
702012030146411/29/12Janus kinase inhibitors for treatment of dry eye and other eye related diseases
712012029591211/22/12Piperazinylpiperidine derivatives as chemokine receptor antagonists
722012027080910/25/12Human transmembrane proteins
732012012285805/17/12Lactam compounds and their use as pharmaceuticals
742012004096402/16/12N-substituted piperidines and their use as pharmaceuticals
752012003517202/09/12Purinone derivatives as hm74a agonists
762012001493701/19/12Human beta-adrenergic receptor kinase polypeptide and methods
772012001592801/19/12Amido compounds and their use as pharmaceuticals
782011025121510/13/11Macrocyclic compounds and their use as kinase inhibitors
792011021296709/01/11Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
802011020775408/25/11Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
812011013678106/09/11Imidazotriazines and imidazopyrimidines as kinase inhibitors
822011008681004/14/11Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d] pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
832011008215904/07/11Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
842011005321703/03/11Polynucleotides encoding signal peptide-containing molecules
852010027933311/04/10Methods of treatment with antibodies to a chemokine expressed in inflamed adenoid
862010025611410/07/10Amido compounds and their use as pharmaceuticals
872010024067109/23/10Substituted heterocyclic compounds
882010020303908/12/103-aminocyclopentanecarboxamides as modulators of chemokine receptors
892010019080407/29/10Macrocyclic compounds and their use as kinase inhibitors
902010017390107/08/10Substituted heterocyclic compounds
912010013740106/03/102-methylprop anamides and their use as pharmaceuticals
922010011950305/13/103-aminocyclopentanecarboxamides as modulators of chemokine receptors
932010009961704/22/10Secreted proteins
942009031840512/24/094-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
952009029194611/26/09Lactam compounds and their use as pharmaceuticals
962009028677411/19/09Purinone derivatives as hm74a agonists
972009028677811/19/09Macrocyclic compounds and their use as kinase inhibitors
982009027468011/05/09Human phospholipases
992009023390309/17/09Azetidine and cyclobutane derivatives as jak inhibitors
1002009021576608/27/09Tetracyclic inhibitors of janus kinases
1012009019788708/06/09Piperazinylpiperidine derivatives as chemokine receptor antagonists
1022009018195907/16/09Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1032009012464905/14/09Aza spiro alkane derivatives as inhibitors of metalloproteases
1042009008844604/02/09Purinone derivatives as hm74a agonists
1052009007626903/19/09Purinone derivatives as hm74a agonists
1062012026367610/18/12Compositions, methods and kits relating to her-2 cleavage
1072012005807903/08/121,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
1082012001498901/19/12Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
1092011031147912/22/11Modulators of indoleamine 2,3-dioxygenase and methods of using the same
1102011022321009/15/11Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1112011022415709/15/11Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1122011017227907/14/11N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
1132011016518807/07/11N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
1142011008683504/14/11Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
1152009029880812/03/09Inhibitors of 11-beta hydroxyl steroid dehydrogenase type i and methods of using the same
1162009019786908/06/09Azepine inhibitors of janus kinases


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Incyte Corporation in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Incyte Corporation with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         


FreshNews promo